Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat

Neuroscience Bulletin

Volumn 31, Issue 5, 2015, Pages 572-588

  Gao, Keming ^a   Yuan, Chengmei ^b   Wu, Renrong ^c   Chen, Jun ^b   Wang, Zuowei ^d   Fang, Yiru ^b   Calabrese, Joseph R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Mental Health Centre of Hongkou District   (China)

Author keywords

akathisia; atypical antipsychotic; bipolar depression; efficacy; extrapyramidal side effects; number needed to treat; somnolence; tolerability; weight gain

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; LAMOTRIGINE; LITHIUM; LURASIDONE; PAROXETINE; QUETIAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

BIPOLAR DEPRESSION; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; REMISSION; REVIEW; TREATMENT RESPONSE; WEIGHT GAIN; ACUTE DISEASE; BIPOLAR DISORDER; FEMALE; MALE; MAXIMUM TOLERATED DOSE; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; TREATMENT OUTCOME;

EID: 84942367058     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-014-1534-0     Document Type: Review

References (44)

1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59: 530–537.
2. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60: 261–269.
3. Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: Results of a U.S. community-based sample. J Clin Psychiatry 2004, 65: 1499–1504.
4. Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005, 66: 1376–1385.
5. Gao K, Wu R, Grunze H, Calabrese JR. Pharmacological Treatment of Acute Bipolar Depression. In: Yildiz A, Ruiz P, Nemeroff C (Eds.). Bipolar Book: History, Neurobiology, and Treatment. New York: Oxford University Press (in press).
6. th Ed. Chichester, West Sussex, UK: Wiley-Blackwell (in press).
7. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008, 69: 302–309.
8. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008, 28: 203–209.
9. Wang Z, Kemp DE, Chan PK, Fang Y, Ganocy SJ, Calabrese JR, et al. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 2011, 14: 131–142.
10. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011, 72: 1063–1071.
11. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014, 155: 20–27.
12. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006, 16: 601–611.
13. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997, 126: 712–720.
14. Wu R, Kemp DE, Sajatovic M, Zhao J, Calabrese JR, Gao K. Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary. Clin Ther 2011, 33: B62–76.
15. Cohen LS. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum, 1988.
16. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 2003, 60: 1079–1088.
17. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012, 201: 376–382.
18. Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, et al. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry 2013, 13: 138.
19. Brown EB, McElroy SL, Keck PE Jr, Deldar A, Adams DH, Tohen M, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006, 67: 1025–1033.
20. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A andomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162: 1351–1360.
21. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26: 600–609.
22. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121: 106–115.
23. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71: 150–162.
24. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71: 163–174.
25. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008, 28: 13–20.
26. Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012, 32: 470–478.
27. Gao K, Pappadopulos E, Karayal ON, Kolluri S, Calabrese JR. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol 2013, 33: 425–431.
28. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72: 1413–1422.
29. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014, 171: 160–168.
30. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014, 171: 169–177.
31. Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008, 8: 1079–1091.
32. Tohen M, Katagiri H, Fujikoshi S, Kanba S. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013, 149: 196–201.
33. Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat 2013, 9: 1145–1157.
34. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66: 870–886.
35. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003, 60: 392–400.
36. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003, 64: 1013–1024.
37. van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70: 223–231.
38. Wu R, Gao K, Calabrese JR, Grunze H. Treatment induced mood instability: treatmentemergent affective switches and cycle acceleration. In: Yildiz A, Ruiz P, Nemeroff C (Eds.). Bipolar Book: History, Neurobiology, and Treatment. New York, USA: Oxford University Press (in press).
39. Chen J, Fang Y, Kemp DE, Calabrese JR, Gao K. Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms. Curr Psychiatry Rep 2010, 12: 512–521.
40. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013, 170: 1249–1262.
41. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64: 543–552.
42. Zimmerman M, Martinez JA, Attiullah N, Friedman M, Toba C, Boerescu DA, et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry 2012, 73: 790–795.
43. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358: 252–260.
44. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Review Guidance: Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review. Rockville, Maryland, USA: Food and Drug Administration, 2005.